INTERVACC
Intervacc is a biotechnology company which develop new vaccines to meet the increasing need for effective vaccines in animal health care.
INTERVACC
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2001-01-01
Address:
Hägersten, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.intervacc.com
Total Employee:
11+
Status:
Active
Contact:
08-120 10 600
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Antagene
Antagene is a biotechnology company which develops and sells DNA tests witin the framework of animal health, veterinary diagnosis.
Biosearch Life
e is a biotechnology company that develops and manufactures products through the innovation of natural ingredients.
Cutech
Cutech is a biotechnology company, engages in the design of informative skin and hair follicle screening models.
LiteVax
LiteVax is a biotechnology company that creates vaccines against infectious and non-infectious diseases.
Oroxcell
Oroxcell is a leading company in developing and creating alternative methods to animal use.
Progentix Orthobiology
Progentix Orthobiology is developing synthetic bone substitutes designed to accelerate bone healing through a novel microstructure.
Current Employees Featured
Official Site Inspections
http://www.intervacc.com
- Host name: premium14.oderland.com
- IP address: 91.201.60.72
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Intervacc"
Intervacc - Crunchbase Company Profile & Funding
Intervacc develops vaccines based on recombinant proteins for use in animal health care. They focus on diagnostics in the animal health market and provide bacteriological and mycological …See details»
About us - Intervacc
Intervacc develop novel veterinary vaccines and the pipeline is based on new technology using recombinant proteins rather than attenuated live strains found in conventional vaccines. This …See details»
Intervacc - Products, Competitors, Financials, Employees, …
Intervacc has received orders from Dechra Pharmaceuticals with an order value equivalent to approximately SEK 5.8 million. Jan 16, 2025. Intervacc Thu, Jan 16, 2025 10:20 CET …See details»
Intervacc Company Profile - Office Locations, Competitors, …
Oct 29, 2024 Intervacc kr8.02 m in annual revenue in FY 2023. See insights on Intervacc including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Intervacc AB - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Intervacc AB of Hägersten, Stockholm. Get the latest business insights from Dun & Bradstreet.See details»
Intervacc AB - Company Profile and News - Bloomberg Markets
Company profile page for Intervacc AB including stock price, company news, executives, board members, and contact informationSee details»
Intervacc AB (STO:IVACC) Company Profile & Description - Stock …
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, …See details»
Intervacc - Funding, Financials, Valuation & Investors - Crunchbase
Intervacc is a biotechnology company that develops vaccines based on recombinant proteins for animal health.See details»
Intervacc - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 18, 2025 Intervacc is a biotechnology company developing vaccines based on recombinant proteins. As of May 2017, the company is working on three projects which are: (a) Strangvac a …See details»
Intervacc AB:Company Profile & Technical Research,Competitor …
Intervacc AB is a company that provides Toxoid, DNA vaccination, Medicine and more. Intervacc AB is headquartered in Sweden . Intervacc AB was founded in 2001.See details»
Investors - Intervacc
Intervacc develops veterinary vaccines based on fusions of recombinant proteins. Our first proprietary vaccine Strangvac ®, a vaccine against the streptococcal infection strangles that …See details»
Intervacc 2025 Company Profile: Stock Performance & Earnings
Information on stock, financials, earnings, subsidiaries, investors, and executives for Intervacc. Use the PitchBook Platform to explore the full profile.See details»
Intervacc - VentureRadar
Intervacc VentureRadar profile. Find out more about Intervacc including the VentureRadar Innovation and Growth scores, Similar Companies and more.See details»
Intervacc AB: Governance, Directors and Executives & Committees ...
Dec 12, 2018 Find the composition of the Board of Directors of Intervacc AB (Nasdaq Stockholm Stock Exchange), the gender parity as well as the age distribution of the insiders.See details»
Intervacc - Overview, News & Similar companies | ZoomInfo.com
Intervacc has announced that Jonas Sohlman has joined the organization as Acting President & Chief Executive Officer. Previously, Andersson served as Chief Financial Officer for Enorama …See details»
Intervacc AB, IVACC:STO profile - FT.com - Financial Times
3 days ago Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine …See details»
Intervacc AB (IVACC) | Investor Relations Data & Reports
Browse Intervacc AB's (IVACC) investor relations materials including 2024 annual reports, financial statements, ESG data, and company filings.See details»
Intervacc Annual Report 2021 - Intervacc - Cision News
Apr 6, 2022 About Us. Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years …See details»
Intervacc (IVACC) Investor Relations Material
Nov 14, 2024 Access Intervacc (IVACC) Investor Relations material, such as Live Earnings Calls, Transcripts, Slides, Reports, and Estimates using QuartrSee details»
Governance Intervacc AB Deutsche Boerse AG - MarketScreener.com
Dec 12, 2018 Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ s candidate vaccine …See details»